Thermo Fisher Scientific Capabilities Update August 2026: CPHI Special Edition

In this presentation, Ian Goodwin of Thermo Fisher Scientific discusses what companies should consider when selecting a CDMO partner in today’s evolving biopharmaceutical industry. He explores the growing pressures around cost, timelines, regulatory expectations, and supply-chain uncertainty, and explains why trust, transparency, proactive communication, and risk mitigation are increasingly important.

The presentation highlights how integrated teams, digital tools, AI, and real-time data can help identify challenges before they impact a program. Goodwin also discusses Thermo Fisher Scientific’s capabilities across biologics, mRNA, viral vectors, small molecules, and sterile fill-finish, as well as its connected manufacturing, cold-chain logistics, analytical, and clinical trial services.

The discussion concludes with the advantages of an interconnected, end-to-end approach — from drug substance and drug product manufacturing through clinical delivery — and how this model can help companies reduce risk, accelerate development, and keep critical milestones on track.